Search
We aimed to assess safety, tolerability, and Plasmodium vivax relapse rates of ultra-short course (3.5 days) high-dose (1 mg/kg twice daily) primaquine (PQ) for uncomplicated malaria because of any Plasmodium species in children randomized to early- or delayed treatment.
Plasmodium knowlesi is a zoonotic parasite that causes malaria in humans. The pathogen has a natural host reservoir in certain macaque species and is transmitted to humans via mosquitoes of the Anopheles Leucosphyrus Group. The risk of human P. knowlesi infection varies across Southeast Asia and is dependent upon environmental factors.
Malaria is a significant public health concern in the Kingdom of Saudi Arabia (KSA). This study aimed to investigate the spatiotemporal distribution of malaria in the KSA between 2017 and 2021.
World-first research from The Kids Research Institute Australia and Curtin University predicts climate change could trigger more than 100 million additional malaria cases and 500,000 additional deaths in Africa by 2050, including substantial impacts on children.
Research to eliminate one of the world’s deadliest diseases – malaria – will be accelerated thanks to a USD $4.7 million grant from the Gates Foundation for scientists at The Kids Research Institute Australia and The University of Western Australia (UWA).
The Malaria Atlas Project (MAP) – which houses the world’s largest malaria database and is at the forefront of efforts to track and tackle the disease – has been awarded more than $16 million by the Bill & Melinda Gates Foundation.
Disruptions of malaria case management caused by the COVID-19 pandemic likely contributed to an extra 76,000 malaria deaths in sub-Saharan Africa, according to analysis by The Kids Research Institute Australia and Curtin University.
A world-leading research team built to tackle malaria has relocated from Oxford University to Western Australia to take advantage of the state’s growing big data talent pool.
Malaria remains a leading cause of morbidity and mortality and is responsible for over 0.5 million annual deaths globally. During the first two decades of this century, scale-up of a range of tools was associated with significant reductions in malaria mortality in the primary risk group, young African children.
The World Health Organization recommends perennial malaria chemoprevention (PMC), generally using sulfadoxine-pyrimethamine (SP) to children at high risk of severe Plasmodium falciparum malaria. Currently, PMC is given up to age two in perennial transmission settings. However, no recommendation exists for perennial settings with seasonal variation in transmission intensity, recently categorized as 'sub-perennial'.